EGFR and breast carcinoma: And the combination of several genes was also commercially used to predict the clinical outcome of breast cancer patients.123 Another widely used marker is EGFR mutations for lung cancer, whose function is closely related to tumour progression through important signalling pathways such as MAPK and AKT/PI3K, and there are also many clinical drugs targeting EGFR.124